Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia


Ciftciler R., DEMİROĞLU H., BÜYÜKAŞIK Y., ALADAĞ KARAKULAK E., AKSU S., HAZNEDAROĞLU İ. C., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.19, sa.3, ss.177-182, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 3
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1016/j.clml.2018.11.016
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.177-182
  • Hacettepe Üniversitesi Adresli: Evet

Özet

The group of patients with refractory acute myeloid leukemia includes those patients who fail standard induction chemotherapy, who relapse within 6 months after first complete remission, and who have relapsed twice or more. The outcome of these patients is usually very poor, with only a small proportion who can be rescued by allogenic hematopoietic stem cell transplantation. The aim of this study is to evaluate the efficacy and feasibility of allogenic hematopoietic stem cell transplantation in patients with refractory acute myeloid leukemia.